JXJuan Xiong

Juan Xiong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juan Xiong has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Chen

    Department of Pediatrics Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University Changsha China

    2 shared publications
  • Ciliu Zhang

    Department of Pediatrics Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University Changsha China

    2 shared publications
  • Fang He

    Department of Pediatrics Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University Changsha China

    2 shared publications
  • Jing Peng

    Department of Pediatrics Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University Changsha China

    2 shared publications
  • Wen Zhang

    Department of Pediatrics Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University Changsha China

    2 shared publications
  • Xiaolu Deng

    Department of Pediatrics Clinical Research Center of Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University Changsha China

    2 shared publications

Latest Publications

  • Integrated genotype–phenotype function analysis reveals distinct pathogenic mechanisms for cognitive impairment in KCNQ2 ‐related disorders

    by Juan Xiong, Haolin Duan, Jun Chen, Xia You, Fang He, Ciliu Zhang, Lifen Yang, Chen Chen, Xiaolu Deng, Li Yang, et al.

    Objective: Pathogenic variants of KCNQ2 lead to a spectrum of disorders including self‐limited familial neonatal‐infantile epilepsy (SeL(F)NIE), developmental and epileptic encephalopathies (DEEs), and neurodevelopmental disorders (NDDs) with intellectual disability (ID). This study aimed to delineate the clinical progression and underlying pathogenesis of these disorders. Particularly, we unraveled the role of gain‐of‐function (GoF) variants in neurodevelopmental impairment. Methods: We conducted a longitudinal study of a 90‐patient Chinese cohort with KCNQ2 ‐related disorders, classified into SeL(F)NIE, DEEs, and NDDs subgroups. Clinical phenotyping was integrated with functional analyses (electrophysiology, biochemistry) of five missense variants in homomeric and heteromeric (with Kv7.3/Kv7.5) channel assemblies. Results: Despite comparable seizure control to SeL(F)NIE (96% vs 100%), the NDDs group exhibited significant cognitive impairment. All deceased patients (8/90) were in the DEEs group. Functional profiling revealed a spectrum from loss‐of‐function (LoF) to GoF. LoF variants (e.g., S247L in DEEs) were linked to severe epilepsy. Crucially, we identified strong GoF variants (P335A/L in NDDs) in the S6‐HelixA domain that confer insensitivity to phosphatidylinositol 4,5‐bisphosphate (PIP 2 ) regulation and are associated with a primary neurodevelopmental phenotype, distinct from the severe epileptic phenotype of established voltage‐sensing domain (VSD) GoF variants. Significance: Our integrated clinical and functional analysis showed that the clinical outcome relies on the functional consequence of a KCNQ2 variant (LoF vs GoF) and its behavior in heteromeric complexes, rather than its mere location. We defined a novel class of strong GoF KCNQ2 variants that are mechanistically and phenotypically distinct, highlighting aberrantly enhanced channel function as a key driver of cognitive dysfunction and presenting new targets for precision medicine.


  • A novel KCNQ2 missense variant in non-syndromic intellectual disability causes mild gain-of-function of Kv7.2 channel

    by Juan Xiong, Shimeng Chen, Baiyu Chen, Wen Zhang, Chen Chen, Xiaolu Deng, Fang He, Ciliu Zhang, Lifen Yang, Ying Wang, et al.


  • SAT0018 Establishing the Content Validity of Omeract Preliminary Flare Questions (PFQ) for Detecting and Measuring Disease Exacerbations in Rheumatoid Arthritis

    by S. J. Bartlett, C.O. Bingham, E. Choy, J. Xiong, G. Boire, B. Haraoui, J. E. Pope, J. C. Thorne, C. A. Hitchon, D. Tin, et al.

    Background Flares in rheumatoid arthritis (RA) are common, poorly defined, and understudied in research and clinic settings. There is an urgent need for a validated tool that can reliably and comprehensively quantify RA disease exacerbations. The OMERACT RA Flare Group is an international collaboration of researchers and clinicians working together to develop an RA flare assessment measure. The rigorous, iterative process of qualitative and quantitative research with patients and health care providers that was used to identify the core set of domains to assess in RA flares was recently ratified by OMERACT attendees. Next, we developed a single item to assess each key domain (pain, function, fatigue, participation, coping and stiffness). Here, we report results of activities to establish the convergent validity of the OMERACT preliminary flare questions (PFQ). Objectives To describe associations between responses to OMERACT PFQ items and similar questions from validated scales and indices commonly used in RA. Methods 919 participants in the Canadian early ArThritis CoHort (CATCH) completed the OMERACT PFQs at routine clinic visits from 11-2011 through 1-2013. Participants rated their pain, function, fatigue, participation, coping and stiffness over the past week using an 11-point numerical rating scale. Measures of association (Pearson, Spearman, polychoric, polyserial) were calculated between PFQ responses and relevant items/indices from the HAQ, SF12, WPAI, RADAI and other commonly used measures. Results 74% were female (74%), 83% White, and 54% completed at least high school. Mean (SD) age was 53.2 (14.7) years and RA duration of 5.9 (3.1) months. Across all, correlations were strongest between the PFQ pain rating and similar pain items from other scales (r’s=.84 to .89). Moderate-strong correlations were evident among PFQ and other items querying function (r’s= .66 to .76), fatigue (r’s= .61 to .85), participation (r’s=.64 to .78) and coping (r’s=.48 to .58). Coping ratings were weakly to moderately related to depressed mood (r=.46), anxiety (r=.33), and stress (r=.10). PFQ stiffness ratings were moderately related to early morning stiffness (r=.61). Conclusions In patients with early RA, there was substantial agreement between single item OMERACT PFQs for each domain and items from validated measures commonly used in RA research and care. These data provide evidence of convergent validity of PFQ items with other validated measures and add to the growing body of evidence supporting the validity of the OMERACT RA Flare Questionnaire. The OMERACT Flare Questionnaire is undergoing additional psychometric evaluation across a variety of RA populations and settings to establish its reliability, validity, and responsiveness prior to release for widespread use among clinicians and researchers. Disclosure of Interest S. Bartlett: None Declared, C. Bingham III: None Declared, E. Choy: None Declared, J. Xiong: None Declared, G. Boire: None Declared, B. Haraoui: None Declared, J. Pope: None Declared, J. Thorne: None Declared, C. Hitchon: None Declared, D. Tin: None Declared, E. Keystone: None Declared, V. Bykerk Grant/research support from: The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. via an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium (UCB) Canada Inc., Bristol-Myers Squibb Canada Co., Abbvie Inc, and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.)

  • FRI0490 The four finger examination technique is superior to the standard two finger technique to detect metacarpal phalangeal joint swelling in rheumatoid arthritis - a validation by power doppler ultrasound

    by E. C. Keystone, M. A. Omair, P. Akhaven, A. Naraghi, D. A. Weber, J. Xiong, S. Mittoo, M. L. Weber

    Background Swollen joints (SJs) are a strong clinical predictor of radiographic progression in rheumatoid arthritis (RA). The metacarpal phalangeal joints (MCP) SJs are particularly relevant since they are the earliest joints demonstrating radiographic progression. Thus, more sensitive detection of less obvious SJs is important for improved assessment of disease activity. A novel four finger (FF) examination technique was developed to be more sensitive than the two finger (TF) technique in the detection of less clinically apparent joint swelling. Objectives To compare the sensitivity of the FF vs. TF technique to detect synovitis by ultrasound (US). Methods We compared the FF vs. TF examination technique in 180 MCPs in 18 RA patients. The population was comprised of 94.4% females, mean age of 55.8 yrs and mean disease duration of 19.9 yrs. Patients were examined twice on the same day by 4 rheumatologists; 2 performed FF and 2 used the TF technique. SJs were determined by palpation defined by being either (1) ballotable or (2) spongy (non-ballotable swelling). TJs were also assessed. We evaluated the agreement between the SJ/TJ examination techniques with US using grey scale, power Doppler (PD) positivity, or the presence of an effusion. Results Consistent with previous literature, the inter-observer agreement (IA) using Kappa statistics was poor to moderate for both SJ techniques. We therefore evaluated only joints in which there was agreement between the 2 examiners for each SJ technique. With the TF and FF techniques respectively, there were 115 & 134 SJs in which there were agreement for the joints being ballotable and 99 & 122 SJs for being spongy. The Kappa agreement between FF and TF techniques respectively, for ballottement by PD was 0.55 vs 0.27; by grey scale 0.35 vs. 0.12, and by effusion: 0.18 vs. 0.08. For SJ detected by being spongy, the relationship between FF and TF was the same, but the Kappas were lower. The agreement between TJs and US was extremely poor with mean Kappas for the 4 examiners for PD of 0.07; for grey scale: 0.06 and for effusion: -0.08. Conclusions The results of this study demonstrate that for MCPs, the FF technique is more sensitive than the TF technique for detection of synovitis as determined by US and therefore a better examination technique for clinical decision making. Of significance, the data provide strong support for the importance of detecting SJs (rather than TJs) as a prognostic guide for structural damage in RA. Disclosure of Interest None Declared